Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Prof. Ziv Amitai Wins Lennox K. Black Prize for Excellence in Biomedical Research

Lennox K
Prof. Amitai Ziv, Head of Sheba’s Rehabilitation Hospital and founder of MSR, the Israel Center for Medical Simulation, has been awarded the prestigious Lennox K. Black Prize for Excellence in Biomedical Research for his contributions to biomedical technology and its use to advance global medical education.

Prof. Ziv, who has published more than 60 papers in international peer-reviewed journals, is a world-renowned expert in medical simulation research and has served the World Health Organization as a member of several expert working groups. In recognition of his work, Prof. Ziv was awarded numerous awards for his humanitarian and educational work around the world, including the 2007 Charles Bronfman Award for Humanitarian Action, the 2007 Michener Honorary Diploma of Health Science Award for Leadership and Commitment to the Applied Health Sciences, and the 2015 Presidential Citation Award on behalf of the Society for Simulation in Healthcare (SSH) for his significant contributions to patient safety through the use of medical simulation technology.


Ayelet’s Miracle: The First Woman to Conceive Four Children Following Ovarian Tissue Cryopreservation

At 21, Ayelet Rozenberg was diagnosed with Hodgkin’s lymphoma. Facing aggressive therapies necessary to save her life, Ayelet feared she would never be able to…
Read More
bowel disease
News Sep 07.

Sheba Partners with Biomica to Advance Inflammatory Bowel Disease Care

As part of the new collaboration, Sheba and Biomica will engage in joint microbiome clinical research to develop better treatments for inflammatory bowel disease (IBD)…
Read More
Hemophilia research
News Sep 05.

New Sheba Study Indicates: Novel Treatment Sharply Reduces Bleed Rates Among Hemophilia Patients

Results indicate that a monthly treatment with Fitusiran significantly reduces bleed rates among both hemophilia A and B patients.
Read More